Tag: Mick Farrell
Resmed taps RLS market for accretive growth
May 1, 2026Liz Beaulieu, Editor
SAN DIEGO – Resmed will buy Noctrix Health, the Pleasanton, Calif.-based developer of the Nidra Tonic Motor Activation therapy for restless leg syndrome (RLS), for $340 million in a move that leverages its existing sleep physician referral network and home medical equipment (HME) delivery channel.
Nidra, which delivers electrical stimulation to the peroneal nerves via a pair of leg-word devices, was authorized for marketing in the United States in 2023, following its designation as a “breakthrough...
Resmed Q2: Mask sales surge as new products, resupply gain traction
January 30, 2026Liz Beaulieu, Editor
SAN DIEGO – Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and Latin America.
Even excluding revenue from VirtuOx, which Resmed acquired in the fourth quarter of 2025, the company still posted double-digit growth in mask revenue during the quarter, according to Chairman and CEO Mick Farrell,...
Resmed’s Mick Farrell takes helm at AdvaMed, highlighting medtech’s push toward holistic, connected care
January 23, 2026Liz Beaulieu, Editor
WASHINGTON – Resmed CEO Mick Farrell has become the first leader from the home care sector to chair the board of directors at AdvaMed, the trade association representing major medtech companies. His appointment signals what AdvaMed officials – and Farrell himself – describe as the continued blurring of boundaries across health care segments.
“Since Mick joined AdvaMed in 2015, the...
AdvaMed names Resmed’s Mick Farrell as new chair
December 15, 2025HME News Staff
WASHINGTON – AdvaMed has announced that Mick Farrell, chairman and CEO of Resmed, will be the next chair of the AdvaMed board of directors. Farrell, who will serve a two-year term beginning in January 2026, succeeds Peter J. Arduini, president and CEO of GE HealthCare. “The entire board and the global industry AdvaMed represents are excited to have Mick as our chair during a rapidly evolving pace of medtech innovation,”...
Resmed builds resilience with strategic US expansion
October 31, 2025Liz Beaulieu, Editor
SAN DIEGO – Resmed is making another strategic investment in U.S.-based manufacturing and distribution, this time in Indianapolis. The move aims to position the company’s inventory closer to its provider customers, according to Mick Farrell, CEO and board chairman.
The new facility, located in “the heart of the Midwest,” is expected to be operational by 2027, Farrell said.
“I can tell you across our footprint here in the U.S., we've...
Resmed advocates for fair reimbursement, stands behind CPAP
August 1, 2025Liz Beaulieu, Editor
SAN DIEGO – Resmed CEO Mick Farrell addressed the latest potential threats to the CPAP therapy market during a recent webcast: The resurgence of Medicare’s competitive bidding program and the development of a new pill to treat obstructive sleep apnea (OSA).
Questioning bid program, savings
Farrell said Resmed is discussing competitive bidding directly with leadership at Health and Human Services and CMS, and working with AAHomecare and AdvaMed to respond to the proposed...
Trump’s tariffs: Resmed ‘well-positioned’ with exemptions, CEO says
April 25, 2025Liz Beaulieu, Editor
SAN DIEGO – Resmed says that U.S. Customs and Border Protection has confirmed that its devices will continue to be exempt from tariffs and, therefore, the company does not expect a material impact on its financial results from any new tariffs.
As of April, the ever-changing tariff landscape included a 10% general tariff on imported products and a 145% tariff on imported products from China.
“I can report that because of the fact that our products are used to treat patients...
Resmed delivers growth
April 24, 2025HME News Staff
SAN DIEGO – Resmed reported third quarter 2025 revenues of $1.3 billion, an increase of 8% over the same quarter the prior year.
Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9%.
Other results for the quarter:
Gross margin improved 140 bps to 59.3%; non-GAAP gross margin improved 140 bps to 59.9%
Income from operations increased 14%; non-GAAP income from operations up 13%
Operating...
ResMed moves to address ‘educational gap’ on PAP devices, GLP-1s
January 31, 2025Liz Beaulieu, Editor
SAN DIEGO – In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep apnea, ResMed is ramping up its education to high-volume prescribers of GLP-1 drugs to reiterate that PAP therapy remains the gold standard.
The FDA announced in late December that it had approved Eli Lilly's Zepbound (tirzepatide) for the treatment of moderate to severe OSA in adults with obesity. It’s approved for use in combination...
ResMed targets resupply, rePAP for growth
October 25, 2024Liz Beaulieu, Editor
SAN DIEGO – ResMed is redoubling efforts to increase resupply with plans to make Snap, a software platform that monitors orders, performance and patient eligibility in real-time, available to all HME providers, not just those using Brightree.
The company reported a “really solid” 10% increase in sales for mask and accessories in the United States, Canada and Latin America for the first quarter of fiscal year 2025, on an “extraordinary comp” of 23% for...